Literature DB >> 30527314

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Mizuki Nishino1, Satoshi Wakai2, Tomoyuki Hida3, Suzanne E Dahlberg4, Masahiro Ozaki2, Hiroto Hatabu3, Hisashi Tachizaki2, Bruce E Johnson5.   

Abstract

PURPOSE: To develop an automated analytic module for calculation of tumor growth rate from serial CT scans and to apply the module and evaluate reproducibility in a pilot cohort of advanced NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors.
MATERIALS AND METHODS: The module utilized a commercially available image-processing workstation equipped with a validated tumor volume measurement tool. An automated analytic software module was programmed with the capability to record and display serial tumor volume changes and to calculate tumor volume growth rate over time and added to the workstation. The module was applied to evaluate the tumor growth rate in a pilot cohort of 24 EGFR-mutant patients treated with EGFR inhibitors, and reproducibility references as tested by two independent thoracic radiologists.
RESULTS: The module analyzed chest CT scans from 24 patients (5 males, 19 females; median age: 61) with a median of 8 scans per patient, totaling 227 scans and provided a graphical display with an automated and instant calculation of tumor growth rate after the nadir volume for each patient. High inter and intraobserver agreements were noted for tumor growth rates, with concordance correlation coefficients of 0.9323 and 0.9668, respectively. Interpretation of slow versus fast tumor growth using previously identified threshold of ≤0.15/month had a perfect interobserver agreement (κ = 1.00), and an excellent intraobserver agreement (κ = 0.895).
CONCLUSIONS: The present study describes the development of an image analytic module for assessing tumor growth rate and the data demonstrates the functionality and reproducibility of the module in a pilot cohort of EGFR-mutant NSCLC patients treated with EGFR-TKI. The image analytic module is an initial step for clinical translation of the tumor growth rate approach to guide cancer treatment in precision oncology.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Computed tomography; EGFR inhibitor; Epidermal growth factor receptor; Lung cancer; Tumor growth rate

Mesh:

Substances:

Year:  2018        PMID: 30527314      PMCID: PMC6294464          DOI: 10.1016/j.ejrad.2018.10.014

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  40 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.

Authors:  Binsheng Zhao; Leonard P James; Chaya S Moskowitz; Pingzhen Guo; Michelle S Ginsberg; Robert A Lefkowitz; Yilin Qin; Gregory J Riely; Mark G Kris; Lawrence H Schwartz
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

3.  Solid tumor models for the assessment of different treatment modalities: I. Radiation-induced changes in growth rate characteristics of a solid tumor model.

Authors:  W B Looney; J S Trefil; J C Schaffner; C J Kovacs; H A Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

4.  Solid tumor models for the assessment of different treatment modalities: systematics of response to radiotherapy and chemotherapy.

Authors:  W B Looney; J S Trefil; J G Schaffner; C J Kovacs; H A Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1976-03       Impact factor: 11.205

5.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Authors:  Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Jänne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

6.  Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy.

Authors:  W B Looney; J S Trefil; H A Hopkins; C J Kovacs; R Ritenour; J G Schaffner
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

Authors:  Gregory J Riely; Mark G Kris; Binsheng Zhao; Tim Akhurst; Daniel T Milton; Erin Moore; Leslie Tyson; William Pao; Naiyer A Rizvi; Lawrence H Schwartz; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

10.  DICOM structured reporting and cancer clinical trials results.

Authors:  David A Clunie
Journal:  Cancer Inform       Date:  2007-05-12
View more
  4 in total

1.  Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib.

Authors:  Mizuki Nishino; Tomoyuki Hida; Sasha Kravets; Suzanne E Dahlberg; Christine A Lydon; Hiroto Hatabu; Bruce E Johnson; Mark M Awad
Journal:  Eur J Radiol Open       Date:  2020-01-28

Review 2.  Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Authors:  Hyesun Park; Lynette M Sholl; Hiroto Hatabu; Mark M Awad; Mizuki Nishino
Journal:  Radiology       Date:  2019-08-06       Impact factor: 11.105

3.  Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.

Authors:  Mizuki Nishino; Junwei Lu; Takuya Hino; Natalie I Vokes; Pasi A Jänne; Hiroto Hatabu; Bruce E Johnson
Journal:  J Thorac Imaging       Date:  2021-09-15       Impact factor: 3.000

4.  Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.

Authors:  Arwa Ali; Monica Dumbrava; Kylie Riddell; Nina Stewart; Robyn Ward; Ahmed K Ibrahim; Melvin Chin
Journal:  BMC Cancer       Date:  2020-04-22       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.